Metropolis Healthcare Ltd

Metropolis Healthcare Ltd share price slipped 1.37% to Rs 588.2. The Company's net profit expanded by 11.62% to Rs 56.88 crore, while revenue from operations slightly gained 6.01% to Rs 450.22 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 70065.21 crore, easing 8.31%. It has inched up 2.76% over last one week and rallied by 18.26% in last one month while the market capitalization of Metropolis Healthcare Ltd has improved by 0.38% and 16.20% in the same period respectively. Profit before tax (PBT) of Metropolis Healthcare Ltd stood at Rs 77.71 crore in Q2 FY26, rallying 26.91% year-on-year, and heading higher 11.40% quarter-on-quarter. EBITDA came in at Rs 106 crore, jumping 29.00% YoY and rising 6.24% sequentially. Total expenses saw a slight increase of 4.55% to Rs 371.43 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 87.1 crore, increasing 10.98% YoY, while employee benefits expense was at Rs 106.98 crore, witnessing a strong rise of 12.06% YoY. For the TTM ended FY26, revenue from operations surged 23.64% to Rs 1645.85 crore, while net profit saw a strong growth of 31.39% to Rs 191.18 crore, compared to previous TTM. EBITDA surged by 31192% to Rs 375.26 crore, and PBT soared 35.80% to Rs 259.18 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 350.7 crore in FY26, as against Rs 262.75 crore in FY25. Metropolis Healthcare Ltd rallied 17.12% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Metropolis Healthcare Limited reported revenue of Rs 450 crore for the quarter ended June 30, 2026, a 17% increase year-over-year, alongside a 27% rise in earnings before interest, taxes, depreciation, and amortization (EBITDA) to Rs 113 crore, according to a press release. The Mumbai-based diagnostics company, led by Ameera Shah, also saw patient volume grow 10% year-over-year and test volume increase 11% year-over-year, with TruHealth revenue growing 22% to Rs 81 crore and Specialty revenue increasing 17% to Rs 178 crore.

Metropolis Healthcare Limited informed the BSE Limited and National Stock Exchange of India that its Nomination and Remuneration Committee approved the allotment of 18,700 equity shares at an exercise price of Rs 2 each, aggregating to Rs 37,400, under the Metropolis -Restrictive Stock Unit Plan, 2020, and the grant of 1,380 units under the Metropolis – Restrictive Stock Units Plan, 2025, and 20,500 options under the Metropolis – Employees Stock Options Plan, 2025.

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Metropolis Healthcare announced that the 26th Annual General Meeting(AGM) of the company will be held on 18 August 2026.

Metropolis Healthcare has allotted 36,900 equity shares under he Metropolis-Restrictive Stock Unit Plan, 2020 on 09 July 2026.

The company said the TruHealth Wellness and Specialty segments are the fastest growing segments for the quarter. In B2C business registered healthy volume growth, driven by increased throughput from the expanded center network. B2B volumes also grew, supported by higher wallet share and new customer acquisition, backed by improved service quality and delivery levels. The company said EBITDA margins improved on a YoY basis in line with guidance. On quarter-on-quarter basis, margins remained largely stable. During the Q4 earnings call, promoter Ameer Shah said the company has guided for a sustainable group EBITDA margin of 27%'28% over the next three years. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. The company's consolidated net profit rose 74.67% to Rs 50.90 crore on 22.99% increase in revenue from operations to Rs 424.68 crore in Q4 FY26 over Q4 FY25.Powered by Capital Market - Live

Aadhar Housing Finance Ltd, Black Box Ltd, Tata Capital Ltd and Craftsman Automation Ltd are among the other losers in the BSE's 'A' group today, 22 June 2026.Metropolis Healthcare Ltd tumbled 4.49% to Rs 527.4 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9318 shares were traded on the counter so far as against the average daily volumes of 8023 shares in the past one month.Aadhar Housing Finance Ltd crashed 4.09% to Rs 494.5. The stock was the second biggest loser in 'A' group.On the BSE, 44078 shares were traded on the counter so far as against the average daily volumes of 1.01 lakh shares in the past one month.Black Box Ltd lost 3.95% to Rs 982.4. The stock was the third biggest loser in 'A' group.On the BSE, 27012 shares were traded on the counter so far as against the average daily volumes of 48825 shares in the past one month.Tata Capital Ltd fell 3.86% to Rs 357.2. The stock was the fourth biggest loser in 'A' group.On the BSE, 3.99 lakh shares were traded on the counter so far as against the average daily volumes of 3.8 lakh shares in the past one month.Craftsman Automation Ltd dropped 3.80% to Rs 9478.85. The stock was the fifth biggest loser in 'A' group.On the BSE, 11122 shares were traded on the counter so far as against the average daily volumes of 10180 shares in the past one month.Powered by Capital Market - Live

Metropolis Healthcare announced that the Board of Directors of the Company at its meeting held on 13 May 2026, inter alia, have recommended the Second Interim dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Profit before exceptional items and tax climbed 93.26% YoY to Rs 69.65 crore in the quarter ended 31st March 2026. The company reported an exceptional loss of Rs 10.69 crore during the quarter. EBITDA stood at Rs 108 crore in Q4 FY26, up 71.3% compared with Rs 63 crore posted in Q4 FY25. EBITDA margin improved to 25.4% in Q4 FY26 as against 18.5% in Q4 FY25. During the quarter, patient volumes grew 11% YoY to 3.5 million, and test volumes increased 14% YoY to 7.6 million, reflecting sustained demand momentum, deeper market penetration and stronger clinician engagement. Revenue per Patient (RPP) improved 11% YoY to Rs 1,210, while Revenue per Test (RPT) increased 8% YoY to Rs 558, supported by favourable mix and higher contribution from specialised testing. The company's B2C revenues grew 20% YoY to Rs 251 crore, driven by higher adoption of preventive and specialized testing, stronger digital engagement and hyperlocal marketing initiatives. B2B revenues increased 28% YoY to Rs 174 crore, aided by strong client retention, hospital outsourcing opportunities, deeper partner relationships and improved service reliability. On a full year basis, the company's consolidated net profit climbed 31.08% to Rs 190.01 crore on 23.64% rise in revenue from operations to Rs 1,645.84 crore in FY26 over FY25. Ameera Shah, promoter and executive chairperson, Metropolis Healthcare, said, 'The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India. With healthcare increasingly moving towards preventive and personalised care, we remain committed to building a differentiated diagnostics platform driven by quality, innovation and customer trust.' Surendran Chemmenkotil, managing director, Metropolis Healthcare, said, 'FY26 was an important year from an execution and operating transformation standpoint for Metropolis. Growth during the year was driven by healthy patient volumes, improved mix and stronger realisations, without any price increase in Q4, reflecting the strength of the underlying demand environment. We also made steady progress in productivity, network utilisation, lab optimisation and acquisition integration, supporting operating leverage and meaningful margin expansion. Going forward, we remain focused on driving sustainable growth, improving network throughput and delivering further efficiency-led margin expansion over the medium term.' Meanwhile, the company's board declared 2nd interim dividend of Rs 1 per equity share of face value Rs 2 each for the financial year 2025-26. The record date for the purpose of payment of interim dividend shall be Tuesday, May 19, 2026. The dividend will be paid within 30 days of its declaration. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics.Powered by Capital Market - Live